Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction

Abstract

Patients receiving therapy for the secondary prevention of myocardial infarction (MI) are still at high risk of a major cardiovascular event or death despite the use of currently available treatment strategy. Vorapaxar, an oral protease-activated receptor antagonist, is a novel antiplatelet drug that has been recently approved to provide further risk reduction. The results of two Phase III trials (thrombin receptor antagonists for clinical event reduction and the TRA 2°P-TIMI 50) have showed that vorapaxar, in addition to standard of care therapy, has the potential to provide further risk reduction in patients with prior MI. A search was made on PubMed on articles related to clinical trials and clinical consideration with the use of vorapaxar. This review article summarizes the results of Phase II trials, Phase III trials, subgroup analysis, precautions, and drug interaction with the use of vorapaxar.

The Thrombin Receptor Restricts Subventricular Zone Neural Stem Cell Expansion and Differentiation

“…PAR1 is also documented to play a role in cell proliferation, differentiation, and migration in other adult stem/progenitor cell niches, including endothelial progenitor cells 18 , 19 and hematopoietic stem cells 20 , 21 . Since orally bioavailable PAR1 small molecule inhibitors are already available in the clinic 22 – 25 , a better understanding of the physiological activities of PAR1 towards neural stems of the adult brain may point to new therapeutic avenues to enhance the generation of new neurons and neuroglia.…”